News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
282,071 Results
Type
Article (14925)
Company Profile (299)
Press Release (266841)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79846)
Career Advice (163)
Deals (13341)
Drug Delivery (39)
Drug Development (50709)
Employer Resources (31)
FDA (5845)
Job Trends (5171)
News (145108)
Policy (10073)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (920)
Accelerated approval (21)
Adcomms (14)
Allergies (85)
Alliances (21763)
ALS (127)
Alzheimer's disease (1038)
Antibody-drug conjugate (ADC) (248)
Approvals (6044)
Artificial intelligence (268)
Autoimmune disease (123)
Automation (9)
Bankruptcy (105)
Best Places to Work (4561)
BIOSECURE Act (6)
Biosimilars (103)
Biotechnology (230)
Bladder cancer (102)
Brain cancer (47)
Breast cancer (349)
Cancer (3185)
Cardiovascular disease (241)
Career advice (148)
Career pathing (8)
CAR-T (225)
CDC (5)
Cell therapy (580)
Cervical cancer (14)
Clinical research (43746)
Collaboration (1176)
Company closure (2)
Compensation (607)
Complete response letters (43)
COVID-19 (1102)
CRISPR (91)
C-suite (576)
Cystic fibrosis (112)
Data (4386)
Denatured (15)
Depression (96)
Diabetes (257)
Diagnostics (1384)
Digital health (13)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (197)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (220)
Earnings (31709)
Editorial (27)
Employer branding (4)
Employer resources (29)
Events (51757)
Executive appointments (631)
FDA (7624)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (10)
Frontotemporal dementia (22)
Funding (998)
Gene editing (188)
Generative AI (22)
Gene therapy (499)
GLP-1 (507)
Government (1151)
Grass and pollen (3)
Guidances (166)
Healthcare (6615)
HIV (19)
Huntington's disease (44)
IgA nephropathy (75)
Immunology and inflammation (197)
Immuno-oncology (43)
Indications (75)
Infectious disease (1214)
Inflammatory bowel disease (160)
Inflation Reduction Act (10)
Influenza (42)
Intellectual property (171)
Interviews (18)
IPO (7349)
IRA (13)
Job creations (867)
Job search strategy (130)
JPM (40)
Kidney cancer (9)
Labor market (24)
Layoffs (244)
Leadership (10)
Legal (1401)
Liver cancer (41)
Longevity (11)
Lung cancer (428)
Lymphoma (254)
Machine learning (24)
Management (7)
Manufacturing (382)
MASH (133)
Medical device (2669)
Medtech (2678)
Mergers & acquisitions (6626)
Metabolic disorders (736)
Multiple sclerosis (107)
NASH (13)
Neurodegenerative disease (238)
Neuropsychiatric disorders (70)
Neuroscience (1980)
Neurotech (1)
NextGen: Class of 2026 (2034)
Non-profit (867)
Now hiring (31)
Obesity (335)
Opinion (126)
Ovarian cancer (132)
Pain (103)
Pancreatic cancer (166)
Parkinson's disease (234)
Partnered (12)
Patents (312)
Patient recruitment (349)
Peanut (44)
People (26708)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15501)
Phase 2 (20326)
Phase 3 (12836)
Pipeline (3429)
Policy (92)
Postmarket research (853)
Preclinical (6545)
Press Release (30)
Prostate cancer (148)
Psychedelics (50)
Radiopharmaceuticals (242)
Rare diseases (666)
Real estate (1448)
Recruiting (12)
Regulatory (9953)
Reports (20)
Research institute (973)
Resumes & cover letters (19)
Rett syndrome (24)
RNA editing (21)
RSV (17)
Schizophrenia (125)
Series A (186)
Series B (140)
Service/supplier (1)
Sickle cell disease (79)
Special edition (19)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2007)
State (1)
Stomach cancer (5)
Supply chain (33)
Tariffs (18)
The Weekly (62)
Vaccines (345)
Venture capital (70)
Weight loss (174)
Women's health (27)
Worklife (2)
Date
Today (90)
Last 7 days (304)
Last 30 days (1247)
Last 365 days (17859)
2026 (2147)
2025 (18102)
2024 (20543)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23357)
2019 (16224)
2018 (11739)
2017 (13751)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (154)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18283)
Australia (3117)
California (7182)
Canada (1870)
China (786)
Colorado (250)
Connecticut (257)
Delaware (239)
Europe (39246)
Florida (920)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (399)
India (36)
Indiana (164)
Iowa (8)
Japan (231)
Kansas (81)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (747)
Massachusetts (5655)
Michigan (110)
Minnesota (252)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (33)
New Hampshire (21)
New Jersey (1669)
New Mexico (13)
New York (1784)
North Carolina (844)
North Dakota (6)
Northern California (3539)
Ohio (180)
Oklahoma (11)
Oregon (24)
Pennsylvania (1294)
Puerto Rico (9)
Rhode Island (26)
South America (215)
South Carolina (9)
Southern California (2849)
Tennessee (40)
Texas (927)
United States (23672)
Utah (98)
Virginia (140)
Washington D.C. (37)
Washington State (595)
West Virginia (1)
Wisconsin (47)
282,071 Results for "intellia therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Gene editing
FDA Lifts One of Two Clinical Holds on Intellia’s ATTR Gene Editing Program
After a patient safety signal and then death, the FDA in October 2025 placed holds on two of the company’s CRISPR programs for hereditary transthyretin amyloidosis.
January 27, 2026
·
2 min read
·
Dan Samorodnitsky
Regulatory
Life-Threatening Liver Toxicity Triggers FDA Freeze on Two Intellia Gene Therapy Studies
The clinical hold comes days after Intellia voluntarily paused enrollment and dosing in the same two studies.
October 30, 2025
·
2 min read
·
Tristan Manalac
Gene therapy
Patient Dies After Receiving Intellia’s CRISPR Gene Therapy Candidate
The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred. Intellia is working with experts to create a risk management program for nex-z.
November 7, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 6, 2026
February 8, 2026
·
1 min read
Press Releases
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 7, 2026
·
1 min read
Press Releases
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN
January 28, 2026
·
6 min read
Rare diseases
Intellia Pauses Phase III ATTR Trials for CRISPR Gene Therapy After Life-Threatening Liver Toxicity
Intellia earlier this year reported a similar grade 4 liver enzyme elevation associated with the gene therapy nexiguran ziclumeran, though analysts at BMO Capital Markets at the time brushed it off as a “non-concern.”
October 27, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 2, 2026
January 5, 2026
·
1 min read
Press Releases
Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates
November 6, 2025
·
13 min read
Gene therapy
Analysts Brush Off Intellia’s Adverse Event but Gene Therapy Safety Concerns Continue
While an adverse event reported in Intellia’s gene therapy trial was a “non-concern” for analysts, it follows a handful of patient deaths in other trials for the modality and sent the company’s stock tumbling in pre-market trading.
May 29, 2025
·
3 min read
·
Annalee Armstrong
1 of 28,208
Next
